Business Ethics in Biotechnology

🥼Business Ethics in Biotechnology Unit 6 – Clinical Trials: Ethics and Human Subjects

Clinical trials are essential for advancing medical knowledge and developing new treatments. They involve carefully designed experiments on human participants to evaluate the safety and effectiveness of medical interventions, following strict scientific protocols and ethical guidelines. Ethical principles like respect for persons, beneficence, and justice guide clinical research. Key regulations, including the Nuremberg Code and Declaration of Helsinki, establish standards for protecting participants. Informed consent, risk assessment, and safeguards for vulnerable populations are crucial aspects of ethical trial conduct.

What Are Clinical Trials?

  • Involve research studies conducted on human participants to evaluate the safety and efficacy of new medical interventions (drugs, devices, procedures)
  • Consist of carefully designed experiments following strict scientific protocols and ethical guidelines
  • Aim to determine if a new intervention works, if it is safe, and if it is better than existing treatments
    • Trials can involve testing new drugs, medical devices, surgical procedures, or behavioral interventions
  • Progress through a series of phases (Phase 1, Phase 2, Phase 3, Phase 4) with increasing numbers of participants and complexity
  • Require approval from regulatory bodies (FDA) and institutional review boards (IRBs) before commencing
  • Can be sponsored by pharmaceutical companies, government agencies, or academic institutions
  • Rely on voluntary participation from individuals who meet specific inclusion and exclusion criteria based on the study's objectives
  • Involve close monitoring of participants' health outcomes and adverse events throughout the trial duration

Ethical Principles in Clinical Research

  • Respect for persons recognizes the autonomy of individuals and their right to make informed decisions about participating in research
    • Researchers must obtain voluntary informed consent from participants or their legal representatives
  • Beneficence requires researchers to maximize benefits and minimize risks to participants
    • Studies should have a favorable risk-benefit ratio and prioritize the well-being of participants
  • Justice ensures fair selection and treatment of participants without discrimination or exploitation
    • Vulnerable populations (children, prisoners, mentally impaired) require additional protections
  • Non-maleficence obliges researchers to avoid causing harm to participants and to promptly address any adverse events
  • Scientific validity demands that studies are well-designed, properly conducted, and yield reliable results that contribute to generalizable knowledge
  • Transparency involves open communication about the study's purpose, procedures, risks, benefits, and results to participants, regulatory bodies, and the public
  • Accountability holds researchers responsible for adhering to ethical principles and professional standards throughout the research process

Key Regulations and Guidelines

  • The Nuremberg Code (1947) established basic principles for human subjects research in response to unethical experiments during World War II
  • The Declaration of Helsinki (1964) set international ethical standards for medical research involving human subjects
    • Emphasizes informed consent, risk minimization, and the primacy of participant welfare over scientific interests
  • The Belmont Report (1979) outlined ethical principles (respect for persons, beneficence, justice) that form the foundation of modern research ethics
  • The Common Rule (1991) is a set of federal regulations governing human subjects research in the United States
    • Requires IRB review, informed consent, and ongoing oversight of research activities
  • ICH-GCP (International Council for Harmonisation - Good Clinical Practice) provides a unified standard for the conduct of clinical trials worldwide
  • HIPAA (Health Insurance Portability and Accountability Act) protects the privacy and security of participants' personal health information
  • FDA regulations (21 CFR Parts 50 and 56) specify requirements for informed consent, IRB review, and investigator responsibilities in clinical trials
  • Involves providing potential participants with clear, accurate, and complete information about the study to enable them to make an autonomous decision
  • Includes details about the study's purpose, procedures, risks, benefits, alternatives, confidentiality measures, and participant rights (voluntary participation, right to withdraw)
  • Must be conducted in a language and manner understandable to the participant, with opportunities for questions and clarification
  • Requires documentation of consent through a signed informed consent form that serves as a legal record
    • Consent forms should be written in plain language, free of technical jargon or coercive language
  • Ongoing process that continues throughout the study, with re-consent required if there are significant changes to the protocol or new information emerges
  • Special considerations apply for vulnerable populations (children, cognitively impaired) who may require assent and/or consent from legally authorized representatives
  • Waivers of informed consent are possible in limited circumstances (minimal risk, impracticable, public benefit) but require IRB approval
  • Therapeutic misconception occurs when participants confuse research with standard medical care and overestimate potential benefits

Vulnerable Populations in Clinical Trials

  • Include individuals with diminished autonomy or increased susceptibility to coercion or exploitation due to age, mental capacity, socioeconomic status, or other factors
  • Children and minors require special protections due to their developing cognitive abilities and dependence on adults
    • Assent (affirmative agreement) from the child and permission from parents or guardians are typically required
  • Pregnant women and fetuses are considered vulnerable due to potential risks to the developing fetus and the woman's altered physiological state
  • Prisoners may feel undue pressure to participate in research due to their restricted liberty and desire for better living conditions
  • Mentally impaired individuals (dementia, intellectual disability, mental illness) may have limited capacity to provide informed consent
  • Economically or educationally disadvantaged persons may be more susceptible to inducements or may not fully understand the research
  • Terminally ill patients may be desperate for treatment and overestimate the potential benefits of experimental interventions
  • Additional safeguards (IRB oversight, consent from legally authorized representatives, risk minimization) are required when including vulnerable populations in research

Risk Assessment and Management

  • Involves identifying, evaluating, and minimizing potential harms to participants while maximizing benefits
  • Risks can be physical (injury, discomfort), psychological (stress, anxiety), social (stigma, discrimination), economic (job loss, costs), or legal (criminal prosecution)
  • Risk-benefit analysis weighs the probability and magnitude of potential harms against the anticipated benefits to participants and society
    • Studies with greater than minimal risk require a compelling scientific rationale and robust risk mitigation strategies
  • Risk minimization strategies include careful study design, safety monitoring, adverse event reporting, and provisions for medical care and compensation
  • Data Safety Monitoring Boards (DSMBs) independently oversee the safety and efficacy of ongoing trials and can recommend modifications or termination if necessary
  • Investigators must promptly report serious adverse events (SAEs) to sponsors, IRBs, and regulatory agencies
  • Adequate insurance coverage and indemnification agreements protect participants and investigators in case of research-related injuries or legal claims
  • Continuous risk assessment and management throughout the trial ensures that evolving risks are identified and addressed in a timely manner

Data Privacy and Confidentiality

  • Involves protecting participants' personal information and ensuring that data is collected, stored, and shared securely and confidentially
  • Informed consent should clearly explain how data will be handled, who will have access, and how confidentiality will be maintained
  • HIPAA and other privacy laws regulate the use and disclosure of protected health information (PHI) in research
    • Researchers must obtain authorization from participants or a waiver from the IRB to use PHI
  • Data anonymization (removing identifiers) or de-identification (coding identifiers) techniques can help protect participant privacy
  • Secure data storage measures (encryption, access controls, firewalls) prevent unauthorized access or breaches
  • Data sharing agreements and transfer protocols ensure that confidentiality is maintained when data is shared with other researchers or institutions
  • Certificates of Confidentiality (CoCs) provide additional legal protections against compelled disclosure of identifiable research data
  • Breaches of confidentiality can cause harm to participants (stigma, discrimination) and undermine trust in the research enterprise
  • Researchers have an ongoing obligation to safeguard participant privacy and confidentiality, even after the study has ended

Ethical Challenges and Dilemmas

  • Balancing scientific validity and ethical considerations when designing and conducting research
    • Ensuring that studies are rigorous and generalizable while minimizing risks and respecting participant autonomy
  • Obtaining truly informed consent from participants who may have limited health literacy or face language barriers
  • Managing conflicts of interest that arise when researchers have financial stakes in the outcomes of their studies
    • Disclosing conflicts and implementing safeguards to prevent bias and maintain public trust
  • Addressing disparities in research participation and ensuring that study populations are representative of the target patient population
  • Navigating cultural differences in attitudes towards research, informed consent, and privacy across diverse global contexts
  • Responding to incidental findings (unexpected medical abnormalities) that emerge during the course of research
    • Developing plans for disclosure and follow-up care that respect participant preferences and clinical significance
  • Ensuring post-trial access to beneficial interventions for participants and communities, particularly in resource-limited settings
  • Maintaining transparency and public trust in the face of negative or inconclusive study results
    • Reporting results accurately and completely, even when they are unfavorable or contradict previous findings
  • Adapting to evolving ethical norms and societal expectations while preserving core principles of respect, beneficence, and justice in research


© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.

© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.